Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9113280 | 0.85 | MTNR1A (0.47) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL9114780 | 0.84 | MTNR1A (0.47) | MTNR1AMTNR1BACACBACACAHTR1D | |
| SCHEMBL15968239 | 0.82 | MTNR1A (0.45) | MTNR1AMTNR1BACACBACACAHTR1D | |
| SCHEMBL9030834 | 0.81 | FFAR1 (0.48) | — | |
| SCHEMBL9030828 | 0.81 | FFAR1 (0.48) | — | |
| SCHEMBL9113027 | 0.81 | MTNR1A (0.44) | MTNR1AMTNR1BACACBACACAHTR1D | |
| SCHEMBL21749917 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL21749916 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL9110400 | 0.80 | ALDH1A1 (0.48) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL3582664 | 0.78 | MTNR1A (0.57) | MTNR1AMTNR1BHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649062-B1 | BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | TAKEDA PHARMACEUTICAL (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8729102-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| CN-103347872-A | Bicyclic compound | TAKAEDA CHEMICAL IND LTD | 2013-10-09 | — | — | CN | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | MTNR1A 2074/4885MTNR1B 1522/4885SLC6A4 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.